Drugs / FT1050
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01527838 | Jan 2012 → Oct 2013 | B-cell chronic lymphocytic leukemia, Hodgkins lymphoma, acute myeloid leukemia | Fate Therapeutics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2014-12-08 | Fate Therapeutics | Results Fate Therapeutics Highlights Effects of Nutrient-Rich Media on Ex Vivo Programmed CD34+ Cells Sourced From Umbilical Cord Blood fatetherapeutics.com ↗
Additionally, ex vivo programmed CD34+ cells exhibited a more than two-fold improvement in HSC engraftment in a xeno-transplantation study in NSG mice at 12-weeks post-transplant. |
| 2014-12-06 | Fate Therapeutics | Results Fate Therapeutics Unveils Preclinical Findings of Newly-Identified Small Molecule Modulator Combination for Ex Vivo Programming of Mobilized Peripheral Blood fatetherapeutics.com ↗ |
| 2011-12-13 | Fate Therapeutics | Results Fate Therapeutics Announces Promising Data From Phase 1B Study of ProHema at the 2011 American Society of Hematology Annual Conference fatetherapeutics.com ↗
Fate Therapeutics, Inc. announced today promising clinical results from a Phase 1b trial of ProHema (FT1050-enhanced umbilical cord blood) as part of double-umbilical cord blood (UCB) transplants in adult patients with hematologic malignancies who have undergone reduced-intensity conditioning therapy. |
| 2011-02-21 | Fate Therapeutics | Results Fate Therapeutics Announces Encouraging Clinical Results and Change in Management fatetherapeutics.com ↗
This excellent news regarding FT1050 clinical development and its orphan designation, and the emerging platform for ex vivo stem cell modulation, place Fate on the best footing possible. |
| 2011-02-21 | Fate Therapeutics | Results Fate Therapeutics Announces Emerging Data From Proof-Of-Concept FT1050 Clinical Trial and Receives Orphan Drug Designation fatetherapeutics.com ↗ |
All press releases naming this drug 5 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FT1050 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01527838 ↗ |
| Known as | 16,16-Dimethyl Prostaglandin E2 | “A Phase I Trial of a Single FT1050 (16,16-Dimethyl Prostaglandin E2) Ex Vivo-Modulated Umbilical Cord Blood (CB) Unit Following a Reduced Intensity Conditioning Regimen For...” NCT01527838 ↗ |
| Modality | Cell therapy | “Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood” NCT01527838 ↗ |